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AbstrACt
Introduction The Canadian Population Attributable Risk of 
Cancer project aims to quantify the number and proportion 
of cancer cases incident in Canada, now and projected 
to 2042, that could be prevented through changes in 
the prevalence of modifiable exposures associated with 
cancer. The broad risk factor categories of interest include 
tobacco, diet, energy imbalance, infectious diseases, 
hormonal therapies and environmental factors such as air 
pollution and residential radon.
Methods and analysis Using a national network, we 
will use population-attributable risks (PAR) and potential 
impact fractions (PIF) to model both attributable (current) 
and avoidable (future) cancers. The latency periods and 
the temporal relationships between exposures and cancer 
diagnoses will be accounted for in the analyses. For PAR 
estimates, historical exposure prevalence data and the 
most recent provincial and national cancer incidence data 
will be used. For PIF estimates, we will model alternative 
or ‘counterfactual’ distributions of cancer risk factor 
exposures to assess how cancer incidence could be 
reduced under different scenarios of population exposure, 
projecting incidence to 2042.
Dissemination The framework provided can be readily 
extended and applied to other populations or jurisdictions 
outside of Canada. An embedded knowledge translation 
and exchange component of this study with our Canadian 
Cancer Society partners will ensure that these findings are 
translated to cancer programmes and policies aimed at 
population-based cancer risk reduction strategies.
bACkgrounD 
Estimates of the current and future burden of 
cancer in Canada attributable to known and 
probable causes of the disease are required 
for allocating prevention resources optimally. 
National1 2 and global cancer incidence 
projections3 suggest that the burden of cancer 
will continue to rise. In Canada and other 
developed nations, this is largely attributable 
to growing and ageing populations. In addi-
tion, despite established associations between 
modifiable risk factors and cancer risk, a suffi-
cient reduction in the prevalence of these risk 
factors has not been achieved in Canada.1–3 
Identifying exposures and interventions with 
the greatest potential impacts of reducing 
cancer risk will aid in implementing preven-
tion programmes and policies to combat this 
growing health challenge.
Several groups, including some members 
of our Canadian Burden of Cancer—Popu-
lation Attributable Risk (ComPARe) Study 
Group, have produced estimates of the 
current burden of cancer attributable to 
lifestyle, environmental and infectious expo-
sures in Canadian national4–6 and provin-
cial7–15 populations. Additional studies have 
estimated the avoidable national16–20 and 
strengths and limitations of this study
 ► We report a detailed and transparent approach for 
conducting large attributable risk estimation proj-
ects to assess the impact of multiple risk factors.
 ► We have considered projections of both the expo-
sure prevalence and cancer incidence with multiple 
approaches, which is an improvement over unreal-
istic fixed projection models.
 ► Long-term projections of exposure prevalence and 
cancer incidence are statistically challenging and 
involve a great deal of uncertainty.
 ► Many of our exposure measures are based on 
self-reported data, which introduces the possibility 
of misreporting.
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global21 cancer burdens in future attributable to single 
exposures. However, population attributable risk (PAR) 
estimates are dependent on risk factor prevalence, which 
vary over time and are population specific. Therefore, 
it is important to frequently update PAR estimates. In 
addition, several methodological extensions to these 
approaches, including modelling the combined impact 
of multiple risk factors and defining the timing of inter-
vention impacts on subsequent cancer incidence, are 
lacking. A comprehensive estimation of the current and 
future cancer burden and the impact of potential reduc-
tions in exposure prevalence on cancer incidence on the 
population are needed.
For the ComPARe Study, we developed a method-
ological framework to estimate the burden of cancer in 
Canada using cancer incidence data (2015) and projected 
incidence trends (2015–2042). The ComPARe study team 
brings together the substantive and quantitative exper-
tise of cancer researchers from across the country. This 
collaborative, pan-Canadian study also involves a part-
nership with the Canadian Cancer Society, a main knowl-
edge end-user for this work, who worked in partnership 
with the researchers throughout this project. To ensure 
methods were rigorously applied and standardised across 
research labs, we developed a methodological framework 
for the estimation of current attributable and future 
avoidable cancers associated with modifiable risk factors. 
This framework extends the work of other groups22–29 and 
is applicable to a range of diseases and populations. In 
this paper, we describe the approach and methods used 
in the ComPARe Study. An overview of earlier methods 
used to estimate PARs and preventable impact fractions 
(PIFs) are presented. We then describe how we used these 
methods in the ComPARe Study, and the innovations that 
we developed to extend them. See figure 1 for an outline 
of our approach.
MethoDs
Figure 1 shows the methodological framework for the 
ComPARe Study. The concept of PAR and population 
attributable fraction was initially developed by Levin in 
1953 to estimate the burden of disease in the general 
population attributable to a given factor.30 Attribut-
able risks are predicated on the assumption that there 
are causal relationships between exposures and disease 
outcomes, and on the concept of the counterfactual, a 
scenario counter to actual experience, where exposures 
to the causal agents no longer exist or can be mitigated.31
Since the initial concept of the PAR method was intro-
duced, several statistical and theoretical extensions to the 
framework have included methods to measure the uncer-
tainty around PARs and the development of PIF. The PIF 
as an extension of PAR to consider situations of complete 
removal of the exposure cannot be assumed.32 The 
impact of a reduction in the prevalence or population 
Figure 1 Scope of project framework for the estimation of current attributable and future avoidable disease burden. 
Abbreviations: CHMS, Canadian Health Measures Survey; CCHS, Canadian Community Health Survey; IARC, International 
Agency for Research on Cancer; WCRF, World Cancer Research Fund; CUP, continuous update project; PIF, potential impact 
fraction; PAR, population attributable risk.
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distribution of an exposure and the subsequent impact 
of an exposure reduction is examined. The PAR and PIF 
form the statistical foundation of the ComPARe Study.
To apply the PAR and PIF to estimate the impacts of 
reducing exposures, three sources of data are essential 
(table 1): (1) the relative risk of incident disease, or risk 
distribution associated with exposure; (2) the proportion 
of the population or cancer cases exposed to the risk or 
protective factor (sex and age-specific exposure preva-
lence); and (3) sex-specific and age-specific disease inci-
dence data. These three elements are needed to estimate 
the proportion of cancer cases that could be prevented, 
based on the PARs or PIFs. In the following sections, we 
present the methods used in the ComPARe Study for esti-
mating the current attributable (PAR) and future avoid-
able (PIF) burdens of cancer.
Identifying risk factors for inclusion
A crucial component of attributable cancer estimation is 
determining which exposures should be included as causal 
for incident cancers. Given the considerable amount of 
epidemiological and basic science literature evaluating 
aetiological associations for cancer, we needed criteria 
to determine the level of evidence required for inclusion 
in our analyses. We developed a hierarchy of evidence 
for the ComPARe Study (figure 2) where quality deter-
mined using STrengthening the Reporting of OBserva-
tional studies in Epidemiology33 guidelines for cohort and 
case-control studies and Meta-analysis Of Observational 
Studies in Epidemiology34 guidelines for meta-analysis. 
The World Cancer Research Fund’s (WCRF) Contin-
uous Update Project35 and the International Agency for 
Research on Cancer’s (IARC) Monographs on the Eval-
uation of Carcinogenic Risks to Humans36 have devoted 
substantial resources, including expert panels, to classi-
fying potentially carcinogenic risks to humans. We used 
the recommendations from these international and 
national panels as our first level of inclusion. IARC group 
1 (carcinogenic to humans) and group 2A (probably 
carcinogenic to humans) carcinogens were included. As 
a second level of evidence, we included exposure–cancer 
site pairs where high-quality meta-analyses of epidemiolog-
ical studies published since the WCRF and IARC reports 
demonstrated consistent associations, as well as IARC 
Group 2B exposures for sensitivity analyses. The exposure 
and cancer site associations included in the ComPARe 
Study are presented in online supplementary table 1.
Table 1 The population attributable risk estimation methods employed for the individual exposures of interest in the 
ComPARe project
Formula for PAR Estimation Exposure
 
Formula 1: PAR =
Pe
(
RR−1)
1+
[
Pe
(
RR−1)] 
 ► Tobacco (secondhand smoke)
 ► UVR risk behaviours
 ► Disinfection by-products
 ► Low vitamin D
 ► Low dietary calcium intake
 ► Helicobacter pylori
 ► Hepatitis B
 ► Hepatitis C
 
Formula 2: PAR = 1−
k∑
i=0
p(c)i
RRi  
 ► Human papillomavirus
 ► Epstein–Barr virus
 ► Human T-cell lymphotropic virus type 1
 ► Human herpes virus 8
 
Formula 3: PAR =
(
pe1× ERR1
)
+
(
Pe2 × ERR2
)
+ ...+
(
Pex × ERRx
)
1+
((
pe1× ERR1
)
+
(
Pe2× ERR2
)
+ ...+
(
Pex×ERRx
))
 
 ► Tobacco (active exposure)
 ► Oral contraceptives
 ► Hormone replacement therapy
 ► Overweight/obesity
 ► Insufficient fruit and vegetable intake
 ► Red meat/processed meat intake
 ► High alcohol intake
 ► Insufficient dietary fibre intake
 ► Physical activity/inactivity
Individualised Methods  ► Overall UV exposure
 ► Air pollution
 ► Radon
 ► Insufficient fruit and vegetable intake
 ► Red meat/processed meat intake
 ► Insufficient fibre intake
 ► Alcohol consumption
ERR, excess relative risk; i, exposure level; k, levels of exposure; PAR, population attributable risk; Pc, proportion of cases at the ith level of 
exposure; Pe, prevalence of exposure in the population; RR, relative risk; UV, ultraviolet; UVR, ultraviolet radiation.
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estimation of attributable cancers
Exposure prevalence data: including latency
The biologically relevant time period from the initiation of 
an exposure to development of disease is highly variable, 
depending on the exposure and cancer site, and it is likely 
to be measured in years or even decades for solid tumours. 
Therefore, we allowed for a period of latency from expo-
sure to cancer incidence and diagnosis in our assessments. 
However, exposure prevalence data were not always avail-
able for the long relevant time periods implied by latency. 
As a proxy measure for each exposure, we extracted the 
median or mean follow-up time from exposure measure-
ment to cancer incidence from large cohort studies. Our 
assessment of quality of the cohort studies was evaluated 
based on their sample size, methods of exposure assess-
ment and length of follow-up, where large cohorts with 
detailed exposure and longer follow-up were considered 
the highest quality. This information concerning the 
latency period was then compared with the time periods for 
which high-quality data on exposure prevalence were avail-
able. We selected prevalence estimates that corresponded 
to the midpoint of the range of potential latency periods, 
as identified from the cohort studies. When these data 
were not available, we assumed a 10-year latency period 
between exposure measurement and cancer incidence, 
or used the closest available prevalence estimates. We 
attempted to strike a pragmatic balance between selecting 
a biologically plausible and relevant period of time and 
feasibly collecting prevalence data. For example, for the 
infectious agents, the latency period was determined by 
the availability of prevalence data. For Helicobacter pylori, 
there was one seroprevalence survey in 1999–2000, and for 
hepatitis B virus and hepatitis C virus, the prevalence data 
were collected from the Canadian Health Measures and 
the Canadian Notifiable Disease Surveillance System from 
2007 to 2012. A diagram of our approach to modelling 
relevant exposures is shown in figure 3.
To estimate the attributable burden of cancer due 
to past exposures in Canada, we developed a hierarchy 
to select prevalence data from Canadian national and 
region-specific data sources, where available. For life-
style exposures we considered data from large Canadian 
cohort studies when data from national population-based 
surveys were not available. For several environmental 
exposures, environmental monitoring data from sites in 
various parts of Canada were used. We collected exposure 
prevalence data overall and, where the data allowed, by 
sex, age and province.
Cancer incidence data
We obtained cancer incidence data for those 18 years 
of age and older from the Canadian Cancer Registry 
Figure 2 The process flow used for selecting risk estimates used in the ComPARe project. *Quality determined using 
STrengthening the Reporting of OBservational studies in Epidemiology33 guidelines for cohort and case–control studies and 
Meta-analysis Of Observational Studies in Epidemiology34 guidelines for meta-analysis.
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(CCR), a national registry of cancer cases covering the 
entire population of Canada, including by province and 
territory. Statistics Canada produces annual data quality 
reports for the CCR and each Canadian province and 
territory has a legislated responsibility for cancer collec-
tion and control, which improves the completeness and 
population coverage of the data.37 Data by province, sex 
and 5-year age group for 2012, being the most recent year 
of national data available at the time of the study (except 
for Quebec data, which were extrapolated from 2010), 
were obtained. Cancer cases were coded in the CCR using 
the International Classification of Diseases for Oncology, 
3rd Edition. Cancer mortality was not considered in this 
study as we were interested in cancer prevention through 
changes in behaviours and exposures. Furthermore, the 
inclusion of survival requires an additional set of model-
ling assumptions related to survival across exposures 
groups, where the evidence base is far less developed.
Estimation of population attributable cancers—including 
uncertainty
The PAR estimation methods employed for the individual 
exposures in the ComPARe Study are presented in table 1. 
Since 95% CIs cannot be easily calculated for PARs,38 
Monte Carlo simulation methods were used to estimate 
95% CIs around PAR estimates, where the relative risk 
(RR) values were drawn from a log normal distribution 
derived from the RR and its associated variance estimated 
from 95% CIs while prevalence values were drawn from a 
binomial distribution with parameter n as the number of 
survey participants and parameter p as the prevalence of 
exposure estimated from the survey. We simulated 10 000 
samples and used the 2.5th and 97.5th percentiles of the 
resulting PAR distribution as the lower and upper limits 
of its 95% CI.39 40
estimation of avoidable cancers
Exposure prevalence data
To estimate the future avoidable cancer burden to 2042, 
it is necessary to project exposure prevalence (eg, to 2032 
if a 10-year latency period is used). We used the expo-
sure prevalence data hierarchy outlined above to identify 
the optimal exposure prevalence data. For these data, we 
focused on sources with longitudinal surveys. For expo-
sures where historical data allowed past trends to be 
observed, one of the several approaches to model future 
prevalence were used. These included linear, logistic 
growth, multinomial logistic regression and exponential 
curves to predict the future proportion of the popula-
tion exposed. Prevalence estimates were projected by sex 
and various levels of exposure prevalence. Models were 
selected based on expert opinion of the visual evaluation 
of the fit to past data trends and by avoiding extreme 
projection scenarios that might have arisen because 
of some overly influential data points. The different 
approaches to model future prevalence reflect different 
potential scenarios. Logistic growth considers that the 
prevalence of exposure would reach a future steady 
state, while multinomial logistic regression predicts that 
the past exposure observed trend would continue rela-
tively unchanged into the future. Exponential and loga-
rithmic curves are a compromise between the logistic and 
multinomial approaches, and involve an assumption that 
the past trend would continue, but at a slower pace. We 
Figure 3 Representation of relevant exposure windows and latency onset considered for the ComPARe project.
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projected exposure data for the combined population 
and for males and females separately, for both national 
and provincial estimates, where the data allowed.
Cancer incidence projections
Cancer incidence frequencies and rates were projected by 
extrapolating past trends using various statistical models. 
In the past, trends over age at diagnosis, year of diagnosis 
(period) and/or year of birth (cohort) as well as hybrids of 
these models have been used. More recently, the age-pe-
riod-cohort41 and the age-drift-period-cohort (Nordpred)42 
models have been widely used. For the ComPARe Study, 
the R package ‘Canproj’43 was used to project cancer inci-
dence from 2012 to 2042. The package projects forward 
to a maximum of 30 years, which suited our needs, based 
on the uncertainty surrounding cancer sites for which 
secondary or primary prevention interventions were being 
scaled up (eg, colorectal, breast, lung and cervical cancers) 
or reduced (eg, prostate cancer).
Canproj combines cancer projection methods that have 
been used in the last 30 years to select the best fitted model 
for the data, using a decision algorithm to identify the most 
appropriate projection (online supplementary figure 1). 
The models available in Canproj include age-only, age-pe-
riod (including common trend and age-specific trend), 
age-cohort and Nordpred42 (age-drift-period-cohort; nega-
tive-binomial distribution may replace the Poisson distri-
bution when over-dispersion appears). All models provide 
projected age-specific incidence rates and counts. Through 
the decision algorithm the Canproj methods produce more 
realistic projection estimates than other approaches, such 
as the Poisson regression method,44 the polynomial regres-
sion and natural spline methods,45 the joinpoint method46 
and the Bayesian Markov chain Monte Carlo methods47 by 
taking advantage of specific aspects of all these methods 
to fit the best model. We evaluated all the findings, inde-
pendently of goodness-of-fit to inspect the face validity of 
the projections.
Defining counterfactual scenarios
Within our avoidable cancers (PIF) framework we exam-
ined a range of exposure prevalence reduction scenarios or 
counterfactuals. Our primary counterfactuals were based 
on population-based interventions that have been shown to 
be beneficial in experimental studies, and which could be 
scaled up to the population level. We conducted a system-
atic literature search of interventions for each exposure 
and identified their effects from reviews, meta-analyses or 
large intervention (individual and/or community level) 
trials. For all exposures, we also included models with fixed 
prevalence reductions of 10%, 25%, 50% and 100% for 
every year between 2018 and 2042.
Potential impact fraction estimation: defining latency of 
interventions
Using projected exposure prevalence, cancer incidence and 
a range of counterfactual scenarios, we then estimated the 
proportions and numbers of avoidable cancers in Canada 
from 2018 to 2042. To present these results, we plotted the 
number of projected cancers under the baseline projec-
tion scenario (if no change in exposure prevalence were to 
occur), followed by the incidence estimated under a range 
of counterfactual scenarios.
To evaluate the assumed fixed latency period, we 
conducted sensitivity analyses using some other assump-
tions for the statistical distribution of latency periods, for 
example, including the uniform, modified Weibull and 
binomial distributions. These alternative distributions were 
each chosen to have a mean of 10 years and range from 0 
to 15 years. Incorporating a distribution of latency periods 
into PIF estimation allowed us to better predict the transi-
tional effect of counterfactual interventions.
Consideration of multiple risk factors and joint effects
As with other burden estimation efforts, our primary 
analyses were focused on the attributable and avoidable 
proportions and numbers of cancers related to individual 
exposures separately. This approach is an oversimplification 
because several exposures might be known to have joint 
impact or interactions on cancer risk. Several well-charac-
terised examples include alcohol and tobacco for various 
cancer sites,48 and overweight or obesity and physical inac-
tivity for colorectal cancer.49 Where possible, we have also 
estimated the impact of multiple risk factors for a series of 
scenarios where the scientific literature has suggested the 
existence of combined or synergistic effects. When expo-
sures are strongly associated and/or their interaction on 
cancer risk departs from multiplicative risk, Levin’s formula 
to estimate PAR of individual risk factors must be used with 
caution. In order to combine PAR across exposures we used 
the Miettinen-Steenland approach for any combined or 
‘summary’ estimates.
sensitivity analyses
Our sensitivity analyses sought to characterise potential bias 
in the available prevalence and risk data. Since we relied 
on data from self-report questionnaires for some expo-
sures, such as alcohol, physical activity and body weight, we 
expected a certain degree of misreporting. In our sensitivity 
analyses, we corrected the reported prevalence by using 
studies that had validated the survey data, based on small 
samples of objective measurements, and then using sex-spe-
cific correction factors. Some exposures had considerable 
(>10%) non-response rates (ie, responded ‘don’t know’ or 
‘refuse to answer’), and for these cases in our main analysis, 
we assumed that non-responders had been unexposed to 
the risk factors in question. In the sensitivity analyses, we 
imputed exposure values using both missing-at-random 
and missing-not-at-random assumptions. For the missing-at-
random scenario, we assumed that non-response was unre-
lated to the exposure status, and hence that the exposure 
distribution among non-responders was identical to that 
of responders. For the missing-not-at-random scenario, we 
assumed that the non-responders were all exposed, and that 
their exposure distribution was identical to the exposed 
survey responders.
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Patient and public involvement
No patients or public were involved in this study protocol.
DIsCussIon
In the ComPARe Study, we developed approaches for 
each step of data collection, analysis, uncertainty estima-
tion and sensitivity analyses in order to arrive at plausible 
PAR estimates for cancer incidence. Furthermore, this 
approach provides a methodologically rigorous frame-
work for long-term projections of cancer burden and 
the relative impacts of different population-based inter-
ventions for cancer prevention. As new cancer risk factor 
prevention strategies are developed, their subsequent 
impact on the future cancer burden can easily be inte-
grated into this project for a comparative analysis of inter-
vention strategies.
The estimates from this project will be relevant to a 
broad audience, ranging from those working in cancer 
prevention and more broadly in health promotion, to 
cancer advocacy groups, public health and healthcare 
planners, health policymakers, clinicians and the public 
to inform priority setting in prevention programming 
and resources; allocation of funding to areas of unmet 
need; and so on. We have developed this project in collab-
oration with the Canadian Cancer Society (CCS), our 
knowledge translation partner. As a primary end-user of 
the data generated from this project, CCS’s input into the 
design and desired output of the project has been invalu-
able. We encourage other groups to plan knowledge 
translation via similar partnership arrangements from the 
initiation phase of the project.
Methodological extensions
During this project we encountered several methodolog-
ical components that were comparatively under-devel-
oped. For example, while several groups have conducted 
large attributable risk estimation projects, few, if any, have 
systematically assessed the impact of multiple risk factors. 
Our examination of approaches for multiple risk factors 
adds to the literature and provides validation of the esti-
mates produced in this project. In addition, we have 
considered projections of both the exposure prevalence 
and cancer incidence data with multiple approaches. 
Previous projects have assumed fixed cancer incidence 
or exposure prevalence for future projections, and both 
are unrealistic. Furthermore, in the application of our 
counterfactual scenarios, we tested and applied several 
lag time models to fit the most likely windows of expo-
sure and their associated subsequent changes in cancer 
incidence. In addition, we have worked in collaboration 
with key knowledge end-users to develop counterfactual 
scenarios that best match realistic expectations for cancer 
prevention programmes.
Limitations
Our framework, while building on previous approaches, 
has a number of limitations. Long-term projections of 
exposure prevalence and cancer incidence are statisti-
cally challenging and involve a great deal of uncertainty. 
Although we have strived to identify the highest quality 
exposure prevalence and cancer incidence datasets, and 
used methodologically sound approaches for modelling, 
our results still need to be interpreted with caution. The 
resulting projections are a direct product of the validity 
of the input data on exposure prevalence and associated 
relative risks. Using data of poor quality or having ques-
tionable validity may result in erroneous projections. 
For this reason, we included population-based, nation-
ally representative surveys to estimate exposure preva-
lence when they were available. Many of our exposure 
measures, particularly for the lifestyle risk and protective 
factors, were based on self-reported data. Where possible, 
we modelled the potential impact of reporting biases on 
our estimates and included analyses focused on directly 
measured exposures.
For several infectious agents including Epstein-Barr 
virus, H. pylori and human papillomavirus, large-pop-
ulation-based estimates of prevalence were not avail-
able for Canada. For these instances, we included case 
series, case–control and cohort studies, as well as popu-
lation-based surveys extracted from populations from 
the USA and if not available, then Western Europe. The 
use of a more sensitive assay for the detection of H. pylori 
has substantially increased the proportion of non-cardiac 
gastric cancers attributable to this infectious agent.50 To 
account for the new gold standard, the included studies 
will be corrected for measurement error.
In terms of cancer incidence projections, we relied on 
the Canproj programme,43 which uses age-period-cohort 
models and the extension of the Nordpred model that 
has been widely used by other research groups for long-
term projections of cancer incidence. However, errors in 
estimates are inevitable when projecting 30 years into the 
future as the models do not account for future changes in 
risk factors (ie, population changes in smoking patterns, 
diet, etc.). In addition, to deal with some of the uncer-
tainty inherent in projections, expert opinion was used 
when the projection model selected by Canproj was 
implausible, which introduces some degree of bias to the 
decisions.
The CCR is a high-quality database with good case 
ascertainment of malignant tumours. Very few incident 
cancer cases are missed in the CCR and therefore any 
bias would be minimal and would not affect our results.37 
However, data for the province of Quebec were extrap-
olated from 2010, as data for 2012 were not available, 
which is a limitation for the national counts. Ethnicity 
was not taken into account in these estimates for various 
reasons. Unlike other national cancer registries, the CCR 
does not provide incidence data by ethnicity. Canada is 
not a populous country and stratifying cancer incidence 
by sex, age and ethnicity would lead to few observations. 
Furthermore, ethnicity-specific risk estimates and prev-
alence data are not available at this time. However, for 
ultraviolet radiation (UVR) exposure, ethnicity was taken 
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into account, as there is a strong interaction between 
UVR and ethnicity.
ConCLusIons
We have described a methodological framework for 
attributable risk estimation and cancer projection that 
extends our previous research in PAR and PIFs. The appli-
cation of this framework will provide estimates of both 
current attributable and future avoidable disease risk in 
Canada. These findings will be of use to those working 
in cancer prevention, public health and healthcare plan-
ners, health policymakers, healthcare providers and the 
general public for a wide range of applications in cancer 
control and prevention.
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